J Neurol Surg B Skull Base
DOI: 10.1055/s-0043-57233
Original Research

Predictors of Remission of Acromegaly following Surgical Treatment in Growth Hormone-Secreting Pituitary Adenoma

Subhas Konar
1   Department of Neurosurgery, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India
Ujwal Yeole
1   Department of Neurosurgery, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India
2   Department of Neurosurgery, Fortis Hospital Kalyan, Mumbai, Maharashtra, India
1   Department of Neurosurgery, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India
Dhananjaya I. Bhat
1   Department of Neurosurgery, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India
3   Department of Neurosurgery, RV Aster Hospital, Bangalore, Karnataka, India
Nishanth Sadashiva
1   Department of Neurosurgery, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India
Bhagavatula Indira Devi
1   Department of Neurosurgery, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India
› Author Affiliations


Background and Objective Surgery is the treatment of choice for growth hormone (GH)-secreting pituitary adenoma. The remission of random GH depends on various factors. We aimed to evaluate the predictors related to remission of random GH following surgical treatment.

Methods We collected the data retrospectively from the chart review from a single unit of neurosurgery. The diagnostic criteria for remission were a random GH < 1 ng/mL or nadir GH < 0.4 ng/mL after an oral glucose tolerance test.

Results Data from a total of 110 (females 62 [56.4%]) patients were available for follow-up and were analyzed. The mean age was 36.5 years (14–69 years). Vision impairments were seen in 39 (35.5%) patients. The mean duration of symptoms before surgery was 34 months. The mean volume of the tumor was 7.2 mL (0.44–109.8 mL). Knosp grade 3 and 4 tumors were seen in 41.5% of cases. The mean preoperative random GH level was 68.9 ng/mL. Transsphenoidal surgery was done in 107 (97.3%) cases. The gross total resection could be done in 36 (32.7%) cases. At 3 months, 25 (26%) patients had a biochemical remission. In univariable analysis, lower Knosp grade, preoperative GH level < 40 ng/mL, gross total resection, and male gender were associated with remission at 3 months. In regression analysis, preoperative GH and male gender were related to remission at 3 months.

Conclusion The preoperative GH level < 40 ng/mL is associated with higher chances of remission after surgery for GH-secreting pituitary adenoma.

Publication History

Received: 25 January 2023

Accepted: 26 March 2023

Article published online:
18 April 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References

  • 1 Sarkar S, Chacko AG. Surgery for acromegaly. Neurol India 2020; 68 (Supplement): S44-S51
  • 2 Fleseriu M, Biller BMK, Freda PU. et al. A Pituitary Society update to acromegaly management guidelines. Pituitary 2021; 24 (01) 1-13
  • 3 Katznelson L, Laws Jr ER, Melmed S. et al; Endocrine Society. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99 (11) 3933-3951
  • 4 Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993; 33 (04) 610-617 , discussion 617–618
  • 5 Campbell PG, Kenning E, Andrews DW, Yadla S, Rosen M, Evans JJ. Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas. Neurosurg Focus 2010; 29 (04) E5
  • 6 Hofstetter CP, Mannaa RH, Mubita L. et al. Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas. Neurosurg Focus 2010; 29 (04) E6
  • 7 Wang Z, Guo X, Gao L. et al. Delayed remission of growth hormone-secreting pituitary adenoma after transsphenoidal adenectomy. World Neurosurg 2019; 122: e1137-e1145
  • 8 Rotermund R, Mader MM, Burkhardt T. et al. Real-life analysis of 280 patients with surgically treated acromegaly: a single-center experience from 2008 to 2015. Neurosurg Focus 2020; 48 (06) E9
  • 9 Nishioka H, Fukuhara N, Horiguchi K, Yamada S. Aggressive transsphenoidal resection of tumors invading the cavernous sinus in patients with acromegaly: predictive factors, strategies, and outcomes. J Neurosurg 2014; 121 (03) 505-510
  • 10 Jane Jr JA, Starke RM, Elzoghby MA. et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab 2011; 96 (09) 2732-2740
  • 11 Briceno V, Zaidi HA, Doucette JA. et al. Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: a systematic review and meta-analysis. Neurol Res 2017; 39 (05) 387-398
  • 12 Phan K, Xu J, Reddy R, Kalakoti P, Nanda A, Fairhall J. Endoscopic endonasal versus microsurgical transsphenoidal approach for growth hormone-secreting pituitary adenomas-systematic review and meta-analysis. World Neurosurg 2017; 97: 398-406
  • 13 Park HH, Kim EH, Ku CR, Lee EJ, Kim SH. Outcomes of aggressive surgical resection in growth hormone-secreting pituitary adenomas with cavernous sinus invasion. World Neurosurg 2018; 117: e280-e289
  • 14 Antunes X, Ventura N, Camilo GB. et al. Predictors of surgical outcome and early criteria of remission in acromegaly. Endocrine 2018; 60 (03) 415-422
  • 15 Shen M, Tang Y, Shou X. et al. Surgical results and predictors of initial and delayed remission for growth hormone-secreting pituitary adenomas using the 2010 Consensus Criteria in 162 patients from a single center. World Neurosurg 2018; •••: S1878-8750 (18)32738-4
  • 16 Yao S, Chen WL, Tavakol S. et al. Predictors of postoperative biochemical remission in acromegaly. J Neurooncol 2021; 151 (02) 313-324
  • 17 Freda PU, Bruce JN, Reyes-Vidal C. et al. Prognostic value of nadir GH levels for long-term biochemical remission or recurrence in surgically treated acromegaly. Pituitary 2021; 24 (02) 170-183
  • 18 Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol 2005; 152 (03) 379-387
  • 19 Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf) 1999; 50 (05) 561-567
  • 20 Sarkar S, Jacob KS, Pratheesh R, Chacko AG. Transsphenoidal surgery for acromegaly: predicting remission with early postoperative growth hormone assays. Acta Neurochir (Wien) 2014; 156 (07) 1379-1387 , discussion 1387
  • 21 Unal TC, Aydoseli A, Ozgen U. et al. A single-center experience of transsphenoidal endoscopic surgery for acromegaly in 73 patients: results and predictive factors for remission. Br J Neurosurg 2021; •••: 1-6 DOI: 10.1080/02688697.2021.1947977.
  • 22 Shirvani M, Motiei-Langroudi R. Transsphenoidal surgery for growth hormone-secreting pituitary adenomas in 130 patients. World Neurosurg 2014; 81 (01) 125-130
  • 23 Yildirim AE, Sahinoglu M, Divanlioglu D. et al. Endoscopic endonasal transsphenoidal treatment for acromegaly: 2010 consensus criteria for remission and predictors of outcomes. Turk Neurosurg 2014; 24 (06) 906-912
  • 24 Kiseljak-Vassiliades K, Carlson NE, Borges MT. et al. Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine 2015; 49 (01) 231-241
  • 25 Sun H, Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M. Factors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly. J Neurol Surg B Skull Base 2014; 75 (01) 47-52